AlphaNet, Inc. is a not-for-profit 501 (c) (3) organization with a unique patient-driven business model that pushes advocacy to a new level, through customized patient care and innovative disease management, while funding research for a cure.
AlphaNet, Inc. was founded in 1995 by three individuals with Alpha-1. They wanted to coordinate and consolidate needed services for Alphas while funding the search for a cure. At that time, Alpha-1 was even less understood than it is today and they fought an uphill battle to gain support and understanding. The concept was to keep any financial resources expended by Alphas, within the Alpha community – channeling “profits” into needed medical research. AlphaNet empowers those diagnosed with Alpha-1 to take charge and improve their lives. Overriding all goals is finding a cure for Alpha-1 and AlphaNet’s commitment to fund that search.
WHAT IS ALPHA-1?
Alpha-1 Antitrypsin Deficiency is one of the most common serious genetic disorders worldwide. The disorder can cause severe lung and/or liver disease and is a leading reason for lung transplantation in adults and liver transplantation in young children. An estimated 120,000 Americans have the disorder, yet only six percent have been accurately diagnosed. Those with Alpha-1 call themselves Alphas.
AlphaNet is incorporated in Florida as a not-for-profit health management corporation and is registered with the IRS as a 501(c)(3) charitable organization.
United States, Puerto Rico, US Virgin Islands